{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T19:27:42Z","timestamp":1758223662258,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmogo.2025.100185","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T10:51:14Z","timestamp":1750243874000},"page":"100185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel blood signature for hepatocellular carcinoma screening"],"prefix":"10.1016","volume":"9","author":[{"given":"K.-M.","family":"Chueng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1974-4806","authenticated-orcid":false,"given":"K.-N.","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8865-0711","authenticated-orcid":false,"given":"S.J.-L.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-S.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-M.","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.-P.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.-Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4236-6599","authenticated-orcid":false,"given":"H.H.-W.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.-K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.K.","family":"Yung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7197-3587","authenticated-orcid":false,"given":"H.-L.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.Y.-M.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.H.-Y.","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.C.C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2025.100185_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmogo.2025.100185_bib2","series-title":"Cancer Epidemiology and Prevention","article-title":"Liver cancer","author":"Thomas London","year":"2017"},{"issue":"10360","key":"10.1016\/j.esmogo.2025.100185_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100185_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/gutjnl-2018-318193","article-title":"Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study","volume":"69","author":"De Toni","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100185_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100185_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"5S","key":"10.1016\/j.esmogo.2025.100185_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.6004\/jnccn.2018.0052","article-title":"Hepatocellular carcinoma: updates to screening and diagnosis","volume":"16","author":"Covey","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100185_bib8","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmogo.2025.100185_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/apt.13841","article-title":"Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"45","author":"Simmons","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.esmogo.2025.100185_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2009.04.005","article-title":"Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma","volume":"137","author":"Marrero","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmogo.2025.100185_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hep.1840190111","article-title":"Prospective study of a-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma","volume":"19","author":"Oka","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.esmogo.2025.100185_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.gastro.2009.10.031","article-title":"Des-\u03b3-carboxy prothrombin and \u03b1-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma","volume":"138","author":"Lok","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.esmogo.2025.100185_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/ajg.2015.100","article-title":"Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"110","author":"Chang","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.esmogo.2025.100185_bib14","first-page":"432","article-title":"Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population","volume":"22","author":"Sherman","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.esmogo.2025.100185_bib15","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1111\/j.1572-0241.1999.01448.x","article-title":"Screening for hepatocellular carcinoma in patients with advanced cirrhosis","volume":"94","author":"Chalasani","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100185_bib16","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1158\/1055-9965.EPI-20-0005","article-title":"Biomarkers for the early detection of hepatocellular carcinoma","volume":"29","author":"Parikh","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100185_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","article-title":"The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers","volume":"23","author":"Johnson","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"year":"2020","series-title":"FDA grants Breakthrough Device Designation for Roche\u2019s Elecsys GALAD Score to Support Earlier Diagnosis of Hepatocellular Carcinoma","author":"Roche Holding","key":"10.1016\/j.esmogo.2025.100185_bib18"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100185_bib19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","article-title":"Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients","volume":"14","author":"Berhane","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100185_bib20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100185_bib43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/jcm12030949","article-title":"The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"12","author":"Guan","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100185_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score","volume":"28","author":"Yang","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100185_bib22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cgh.2022.03.028","article-title":"GALAD score for HCC screening and surveillance","volume":"21","author":"Sachan","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2025.100185_bib23","first-page":"672","article-title":"Current status of the GALAD and BALAD biomarker models for hepatocellular carcinoma","volume":"12","author":"Roberts","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100185_bib24","article-title":"Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis","volume":"4","author":"Wong","year":"2022","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100185_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jhep.2021.09.025","article-title":"An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B","volume":"76","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100185_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmogo.2025.100185_bib27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmogo.2025.100185_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmogo.2025.100185_bib29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.esmogo.2025.100185_bib30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmogo.2025.100185_bib31","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/ajg.2014.157","article-title":"Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy","volume":"109","author":"Lee","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.esmogo.2025.100185_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3350\/cmh.2016.0086","article-title":"Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.esmogo.2025.100185_bib33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhep.2018.02.032","article-title":"Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B","volume":"69","author":"Hsu","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmogo.2025.100185_bib34","article-title":"Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis","author":"Sharma","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.esmogo.2025.100185_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047687","article-title":"Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients","volume":"7","author":"Hann","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.esmogo.2025.100185_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.615203","article-title":"ALT flare predicts hepatocellular carcinoma among antiviral treated patients with chronic hepatitis B: a cross-country cohort study","volume":"10","author":"Du","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100185_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1053\/j.seminoncol.2014.03.006","article-title":"Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype","volume":"41","author":"Carr","year":"2014","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100185_bib38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12876-018-0908-6","article-title":"Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma","volume":"18","author":"Hu","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"13","key":"10.1016\/j.esmogo.2025.100185_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.21037\/atm.2017.06.30","article-title":"Prognostic value of red blood cell distribution width in hepatocellular carcinoma","volume":"5","author":"Goyal","year":"2017","journal-title":"Ann Transl Med"},{"issue":"25","key":"10.1016\/j.esmogo.2025.100185_bib40","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.3748\/wjg.v21.i25.7895","article-title":"Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: systematic review and meta-analysis","volume":"21","author":"Pang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.esmogo.2025.100185_bib41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/IJGM.S150312","article-title":"The utility of biomarkers in hepatocellular carcinoma: review of urine-based 1H-NMR studies\u2013what the clinician needs to know","volume":"10","author":"Cartlidge","year":"2017","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.esmogo.2025.100185_bib42","first-page":"1","article-title":"Surgery and portal hypertension","volume":"1","author":"Child","year":"1964","journal-title":"Major Probl Clin Surg"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T10:00:23Z","timestamp":1758189623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819825000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"alternative-id":["S2949819825000548"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100185","relation":{},"ISSN":["2949-8198"],"issn-type":[{"type":"print","value":"2949-8198"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel blood signature for hepatocellular carcinoma screening","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100185"}}